/L. Platelet engraftment was defined as the first of 7 consecutive days with a platelet count ⩾ 20 × 10 9 /L without transfusion support. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria, version 4.
Renal responses were assessed at 6, 12 and 24 months. Hematologic responses (HRs) were determined by the International Myeloma Working Group Criteria or the revised International Society of Amyloidosis Criteria, when available 9, 10 and were assessed at 1, 3, 6 and 12 months, and approximately every 3-6 months thereafter. Free light chain (FLC) assays were performed at diagnosis, before auto-HCT, and at each subsequent evaluation.
Primary endpoints were OS and PFS. Secondary endpoints were TRM, toxicity rates, hematologic and renal response rates, and the correlation between hematologic and renal responses. Predictors of OS and PFS were evaluated using Cox proportional hazards regression analysis.
Patient characteristics are summarized in Table 1 . Median bone marrow plasma cell infiltration at diagnosis was 6% (range, 1-40%). Forty-one (74.5%) patients had AL with o 10% bone marrow plasma cells at diagnosis (AL only). Fourteen (25.5%) patients had AL with 410% bone marrow plasma cells (PC) at diagnosis (AL+PC410%).
In all, 42 (76%) patients received induction therapy before auto-HCT, 33 (60%) with novel agents: immunomodulatory drugs (IMiD)-based with lenalidomide in 7 (13%) patients and protieasome inhibitors (PI)-based with bortezomib in 26 (47%) patients. Nine (16%) received induction with conventional agents: dexamethasone in 5 (9%), melphalan based in 3 (5%) and cladribine in 1 (2%) patient. Median time to neutrophil and platelet engraftment was 10 (range, 7-15) and 12 (range, 6-23) days, respectively. Grade 2-4 nonhematologic toxicities included nausea in 23 (42%), infection in 18 (33%), diarrhea in 15 (26%), mucositis in 12 (22%) and cardiovascular events in 11 (20%). Renal toxicity was seen in 7 (13%) patients. Six patients died within 100 days and 7 died within 1 year, with 100-day and 1-year TRM of 11% (95% confidence interval (CI) 5-23) and 13% (95% CI 6-26), respectively. Causes of death at 1 year included infection/sepsis/ multiorgan failure in 6 patients and sudden cardiac death in 1 patient. There was a significant decrease in the TRM when comparing auto-HCT performed after 2008 with those performed before 2008 (9% vs 20%).
Overall HR was observed in 43 (86%) of 50 evaluable patients after auto-HCT, with 8 (16%) CR, 12 (24%) very good partial responses (VGPR) and 23 (46%) PR. This compares with 21 of 51 patients (41%) who achieved a HR before auto-HCT. Median time to HR was 3.1 (range,1-24) months. A total of 50, 42 and 35 patients were evaluable for renal response at 6, 12 and 24 months, respectively. Renal responses were seen in 8 (16%), 13 (31%) and 17 (49%) patients at 6, 12 and 24 months, respectively. Seventeen of 35 evaluable patients achieved a renal response at 2 years. There was no difference in renal response between patients achieving 4VGPR (50%), PR (50%) and o PR (33%, P = 0.67). Two patients required hemodialysis before auto-HCT and remained hemodialysis dependent afterward.
With a median follow-up of 37 (range, 4-126) months, the estimated 3-year PFS and OS rates were 54% and 73%, respectively (Figure 1 ). At last follow-up, 31 (56%) patients were alive and in remission.
On multivariate analysis, patients not treated with IMid or PI-based induction and dFLC426 mg/dL had significantly shorter 3-year PFS (15% vs 83%, HR = 7.6, P = 0.002) and significantly shorter 3-year OS (49% vs 95%, HR = 9.5, P = 0.004).
Our results support the role of auto-HCT by demonstrating 480% HR rate and almost 50% renal response rate at 2 years. Use of induction therapy and a lower disease burden at the time of auto-HCT, as defined by dFLC ⩽ 26 mg/dL, were associated with longer PFS and OS in a multivariate model.
The association of organ response with HR was not unequivocal in our study owing to small numbers and almost 30% patients being inevaluable for a response. We saw a steady improvement in renal response over 2 years, with 16%, 31% and 49% renal responses at 6, 12 and 24 months, respectively. In a similar study from Mayo Clinic, Leung et al. 11 reported a renal response rate of 61% at 2 years. Although the patients were comparable, a lower response in our cohort may have been due to the inclusion of dialysis-dependent patients, use of a lower dose of melphalan in a subset of patients, a lower rate of hematologic CR and a smaller number of patients evaluable for renal response.
Huang et al. 12 conducted a randomized clinical trial where patients either received induction with bortezomib+dexametha-sone or no induction before HD melphalan and auto-HCT. Renal response at 2 years was 75% in the induction arm and 53% in the non-induction arm. The better renal response rate may have been due to a lower baseline serum creatinine (0.8 vs 1.2 mg/dL in our study), a higher hematologic CR in his study (68%) and the uniform use of bortezomib in patients treated on the bortezomib arm.
The role of induction therapy before auto-HCT in AL is evolving. However, several studies have failed to show improvement in outcomes. Perz et al. did not show any improvement in HR with the use of vincristine, adriamycin, dexamethasone induction before auto-HCT and the induction treatment was associated with 7% mortality. 13 Some more recent studies, however, support the role of PI or IMiD-based induction in improving outcomes after auto-HCT. 12 The significance of reduction of FLC as a predictor of survival was first reported by Dispenzieri et al.
14 A recent report from the National Amyloidosis Center in the United Kingdom identified the magnitude of the FLC response at 6 months from baseline as a strong predictor of PFS and OS. 15 HD melphalan is nephrotoxic, and some studies have reported a high risk of renal toxicity. In our study, grade 2-3 renal toxicity was seen in 7 patients (13%), and was reversible. All 7 patients had prior renal insufficiency. Forty-two (76%) patients were transplanted between 2006 and 2011, which may be one of the reasons for a relatively short median follow-up of 37 months. We showed a decrease in TRM after 2008, likely due to better patient selection, use of induction therapy and improvements in supportive care.
HD melphalan followed by auto-HCT is a safe and effective treatment option for selected patients with AL with renal involvement, with high rates of hematologic and renal responses, long PFS and OS, and acceptable rates of toxicity. Abbreviations: auto-HCT = autologous hematopoietic stem cell transplantation; dFLC = absolute difference between involved and uninvolved serum-free light chains; Dx = diagnosis; eGFR = estimated glomerular filtration rate; GI = gastrointestinal; Rx = treatment.
